Business Wire

STEER-ENGINEERING

Share
STEER Gives Boost for Horlicks Production, GSK Acknowledges Technology

STEER Engineering, creator of advanced materials platform technologies that effectively transform and functionalise materials in the fields of plastics, pharmaceuticals, food & nutraceuticals, biomaterials and biorefining, announced that it has reached an out-of-court settlement with Glaxo Smith Kline Group (GSK) with regard to the use of their revolutionary technology to produce Horlicks.

Following the settlement, GSK has issued a public statement acknowledging STEER’s contribution in creating step change technology to produce Horlicks. GSK said, “Using STEER’s state-of-the-art technology, high quality extruders, and dedicated personnel, the project has brought a new-to-world technology to fruition, involving numerous improvements compared to the traditional way Horlicks is made. The new process requires only half the footprint of a traditional factory, uses a fifth of the water and reduces the energy usage by 80%.”

Stating that the two companies have reached a satisfactory settlement, the Managing Director of STEER, Dr. Babu Padmanabhan said, “There is no other technology available in the market that has this immense cost benefit and extraordinary performance. Apart from Horlicks, the technology can be used for the manufacture of other food ingredients. STEER will continue to remain focused on supporting India’s quest in bridging the nutrition gap and help ensure food supply-demand stability.”

It may be recalled that in December 2018, STEER had gone to court seeking protection of the technology and know-how it had provided to GlaxoSmithKline Group (GSK) for manufacture of Horlicks, after GSK announced the deal with Hindustan Unilever Limited for its Consumer Healthcare business in India, leading to IP issues which have been settled.

About STEER

STEER is a creator of advanced material platform / manufacturing technologies that transform functionality of differentiated plastics, pharmaceuticals, food & nutraceuticals and biomaterials. Founded in 1993 by Dr. Babu Padmanabhan with a vision to “steer a new world” – a world that is healthy and sustainable, STEER today has 5 global offices and 10 satellite offices, serving over 39 countries and employs over 500 gifted engineers, scientists and technicians across the globe. With 60 patents for breakthrough innovations, the company is committed to the design, creation and implementation of game-changing continuous process technologies.

Link:

ClickThru

Social Media:

https://www.facebook.com/STEERWorld/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model4.11.2025 16:48:00 CET | Press release

Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receiving Tamoxifen (TAM) or Abemaciclib (ABE)Tumor Reduction: Zeta-BC-007 combinations reduced tumor volume by up to 66%, compared to 34% (TAM) and 15% (ABE)Synergistic Cytotoxicity: NaN and ABE together decreased cell proliferation by 60% in vitro, suggesting synergistic effectsNo Tumor Activity: Histology revealed no ki67 staining and increased necrosis in Zeta-BC-007-treated tumorsImmune Activation: Treated mice showed elevated macrophage infiltration and increased circulating monocytes Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME

A New Era Begins: Visionaries Unite to Shape the Next 50 Years of Tourism at TOURISE4.11.2025 16:35:00 CET | Press release

More than 120 global leaders will convene in Riyadh for the inaugural TOURISE Summit this November, bringing together the largest cross-sector gathering covering all industries that benefit from the trillion dollar tourism sector. From sports, entertainment, media, transport and aviation; representatives from government, business and non-profits will join Expedia, Google, Amadeus, Accor, Nikki Beach, Red Sea Global, Certares and the Public Investment Fund (PIF). From headline panels and visionary keynotes to fireside chats and immersive sessions, TOURISE will spotlight the forces transforming global tourism, and the ideas shaping what comes next for the future of tourism. Get ready to witness history in the making. Over three electrifying days, across two dynamic stages, more than 120 of the world’s most influential visionaries, change-makers, and industry pioneers will converge at the inaugural TOURISE Summit – the boldest global platform designed to unite governments, businesses, inv

Digital Access Reaches Four in Five People Worldwide, DCO’s DEN 2025 Finds4.11.2025 16:35:00 CET | Press release

The Digital Cooperation Organization (DCO), the international organization dedicated to advancing inclusive and sustainable digital economies, today launched the Digital Economy Navigator (DEN) 2025 at the Second World Summit for Social Development (WSSD2) in Doha. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104849013/en/ From left to right: H.E. Deemah AlYahya, Secretary General of the Digital Cooperation Organization - H.E. Imaan Sulaiman Ibrahim, Honorable Minister of Women Affairs and Social Development, Federal Republic of Nigeria - Alaa Abdulaal, Chief of Digital Economy Insight at the Digital Cooperation Organization. (Photo: AETOSWire) The second edition of the Navigator provides the most comprehensive analysis to date of global digital-economy maturity. Covering 80 countries representing 94 per cent of global GDP and 85 per cent of the world’s population, the report draws on 145 indicators and a survey of more

GEOLOG Unveils the KickMaster™ Flow-Meter Family for Extreme Well Conditions4.11.2025 16:33:00 CET | Press release

Patented instruments deliver reliable Flow-In/Flow-Out, density, and temperature data in high gas-cut and solids-laden muds for onshore and deepwater operations GEOLOG, the largest independent surface-logging company and a pioneer in applying AI to formation evaluation and automated drilling performance, today announced the immediate availability of KickMaster™, a patented family of flow meters engineered to provide accurate, real-time measurements in the most demanding drilling environments. Developed by GEOLOG’s in-house R&D team, KickMaster™ addresses long-standing challenges in measuring heterogeneous mud flows. The system delivers reliable flow, density, and temperature data during critical drilling events, enabling faster detection, better decision-making, and improved well control. Three engineered models for precise flow managementFlow-Out Meter - For standard and high-volume mud returns. Operates reliably with >40% gas in mud and introduces ~70% lower backpressure than typical

Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium4.11.2025 16:04:00 CET | Press release

Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRIFirst-of-its-kind single intratumoral injection for MBC to the spineTreated lesions showed full bone regeneration with reconstitution of trabecular bone, and no skeletal related events; mean lesion defect volume decreased by 87.9% at day 180.Therapeutic spread extended to nearby non-treated lesions, also achieving complete response within the same vertebral body Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions”, has been accepted and will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 10, 2025. The abstract

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye